Hohberg et al. observed significant differences (p < 0.01) in the ratios of lymph node, bone lesion, and tumor uptake to kidney uptake on pretherapeutic PSMA PET/CT between responders and non-responders (with response defined as a PSA level decline of at least 50%). The gene discussed is KLK3; the disease is neoplasm.